ClinicalTrials.gg
Not yet recruitingNCT07060040Updated Jul 11, 2025

The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status

An interventional study of BOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g and Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g in ESRD (End-Stage Renal Disease) and Dialysis, sponsored by Buddhist Tzu Chi General Hospital. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Buddhist Tzu Chi General Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Study summary

The aim of this study is to evaluate the effects of a specialized oral nutritional supplement (SF) enriched with BCAAs, omega-3 fatty acids, and dietary fiber on improving the nutritional status of dialysis patients with mild to moderate malnutrition, and thereby alleviating fatigue and enhancing quality of life. We will assess various aspects of protein-energy wasting (PEW), as well as changes in the Malnutrition Inflammation Score (MIS), Geriatric Nutritional Risk Index (GNRI), fatigue, appetite, serum BCAA levels, uremic toxins, and gut microbiota composition.

Read the detailed description

Protein-energy wasting (PEW) is highly prevalent in dialysis patients. If not promptly addressed, PEW increases the risk of falls, disability, fractures, hospitalization, and mortality, while significantly impairing quality of life. In clinical care, nutritional supplementation can prevent the onset of PEW and improve quality of life by reducing the severity of malnutrition. Numerous studies and meta-analyses have shown that dietary fiber can help reduce uremic toxins in CKD and dialysis patients. Additionally, research has shown that the loss of branched-chain amino acids (BCAAs) during dialysis can lead to poor appetite, fatigue, and increased risk of PEW. In elderly hemodialysis patients, supplementation with 12 g/day of BCAAs has been shown to reduce anorexia and significantly improve nutritional status.

The aim of this study is to improve the nutritional status of dialysis patients with mild to moderate malnutrition by providing a specialized formula (SF) supplement enriched with branched-chain amino acids (BCAAs), omega-3 fatty acids, and dietary fiber. The ultimate goal is to alleviate fatigue and enhance quality of life. We will simultaneously evaluate changes in multiple aspects of protein-energy wasting (PEW), the malnutrition inflammation score (MIS), the Geriatric Nutritional Risk Index (GNRI), fatigue levels, appetite, serum BCAA concentrations, uremic toxins, and gut microbiota composition.

02

Conditions studied

  • ESRD (End-Stage Renal Disease)
  • Dialysis

Keywords

  • Branched-chain amino acid
  • Protein-energy malnutrition
  • fiber
  • omega-3
  • oral nutritional supplements
  • dialysis
03

In context

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

This study's planned enrollment of 100 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

Buddhist Tzu Chi General Hospital is the lead sponsor of 88 studies on the registry; 20 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ESRD who have been receiving dialysis for more than three months
  • Serum albumin (Alb) ≤ 4.0 g/dL, or (BMI) ≤ 20, or normalized protein catabolic rate (nPCR) ≤ 0.8
  • Male or female patients aged 20 years or older

Exclusion criteria

Exclusion Criteria:

  • Serum albumin (Alb) \< 3.0 g/dL
  • Known allergy or intolerance to any component of the product, or deemed by a physician to be unable to complete the trial
  • Patients who refuse to sign the form or are unable to follow study instructions
  • Pregnant or breastfeeding women
  • Patients with severe illnesses (including burn injuries), undergoing major surgery, with abnormal liver function (GOT and GPT levels more than 5 times the ), or with (6) Participation in another clinical trial of drugs or concurrent use of investigational drugs within 30 days prior to or during this trial (7) Any other serious medical condition as determined by the investigator that would make the patient unsuitable for participation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Experimental formula

    BOSCOGEN 18% Protein ONS (240ml)

    Dietary Supplement: BOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g

  • Active comparator
    comparative formula

    Fresubin dialysis ONS (200 ml)

    Dietary Supplement: Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g

Interventions

  • Dietary supplementBOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g

    Oral nutritional supplementation: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g

  • Dietary supplementFresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g

    Fresubin dialysis ONS (200 ml): Energy 300 kcal, Protein 20 g, BCAA - mg, Omega-3 fatty acid - g, fiber 0.2 g

06

What researchers measure

Primary outcomes

  1. Change in Malnutrition Inflammation Score (MIS)

    Change in total score of MIS (range 0-30; higher scores indicate worse nutritional status)

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Change in Geriatric Nutritional Risk Index (GNRI)

    Change in GNRI score calculated using serum albumin and body weight (higher scores indicate better nutritional status)

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Change in serum albumin concentration

    Change in serum albumin level (g/dL)

    Time frame: From enrollment to end of treatment (12 weeks)

  4. Change in serum pre-albumin concentration

    Change in serum pre-albumin level (mg/dL)

    Time frame: From enrollment to end of treatment (12 weeks)

  5. Change in Protein-Energy Wasting (PEW) status

    Change in PEW status based on ISRNM criteria (present/absent)

    Time frame: From enrollment to end of treatment (12 weeks)

  6. Change in body composition

    Change in body composition including lean mass (kg) and fat mass (kg) as measured by bioimpedance

    Time frame: From enrollment to end of treatment (12 weeks)

Secondary outcomes

  1. Serum BCAA concentration

    Change in serum BCAA concentration

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Serum indoxyl sulfate concentration

    Change in serum indoxyl sulfate level

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Serum p-cresyl sulfate concentration

    Change in serum p-cresyl sulfate level

    Time frame: From enrollment to end of treatment (12 weeks)

  4. Brief Fatigue Inventory - Taiwanese version

    Brief Fatigue Inventory - Taiwanese version (range 0-10; higher scores indicate greater fatigue)

    Time frame: From enrollment to the end of treatment at 12 weeks

  5. Stool Form Assessment

    Bristol Stool Form Scale (a 7-point scale used to classify stool types, with higher score indicates looser stool consistency or more severe diarrhea)

    Time frame: From enrollment to the end of treatment at 12 weeks

  6. Change in handgrip strength

    Maximal and average handgrip strength (kg) will be measured using a hand dynamometer.

    Time frame: From enrollment to end of treatment (12 weeks)

Other outcomes

  1. Change in gut microbiota composition

    Gut microbiota composition (stool), Alpha and Beta diversity indices

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Dec 2027, 29 months later.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 29 months is above that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2025
First posted
Jul 11, 2025
StartEst.
Jul 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07060040
Lead sponsor
Buddhist Tzu Chi General Hospital
Collaborators
Multipower Enterprise Corp.
Responsible party
Yu-Li Lin (Director, Center for Chronic Kidney Disease Prevention and Care, Buddhist Tzu Chi General Hospital) — Principal investigator
First posted
Jul 11, 2025
Start date
Jul 2025 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion